100.00% -1.90

Atyr Pharma Inc (LIFE)

Relative Volume:

ネットキャッシュフロー:

Atyr Pharma Inc Stock (LIFE) Company Profile

Atyr Pharma Inc

858-731-8389

3545 John Hopkins Court, Suite 250, San Diego, CA

LIFE's Discussions on Twitter

Atyr Pharma Inc Stock (LIFE) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2021-10-12	開始されました	RBC Capital Mkts	Outperform
2021-09-21	開始されました	Piper Sandler	Overweight
2021-05-10	開始されました	Laidlaw	Buy
2020-08-17	アップグレード	H.C. Wainwright	Neutral → Buy
2020-03-04	開始されました	ROTH Capital	Buy
2020-03-02	開始されました	Oppenheimer	Outperform
2018-02-14	ダウングレード	JP Morgan	Neutral → Underweight
2017-09-07	開始されました	Piper Jaffray	Overweight
2016-12-13	ダウングレード	JP Morgan	Overweight → Neutral
2015-12-16	開始されました	Citigroup	Neutral
2015-06-01	開始されました	Citigroup	Buy
2015-06-01	開始されました	JP Morgan	Overweight

Atyr Pharma Inc (LIFE) 最新ニュース

Atyr Pharma Inc (LIFE) 財務データ

Atyr Pharma Inc (LIFE) インサイダートレーディング

インサイダートレーディング	関係	日付	取引	コスト	#株式	値 ($)	#株式総数
SCHIMMEL PAUL	Director	Jul 22 '24	Buy	1.74	41,052	71,500	354,075
SCHIMMEL PAUL	Director	Jul 23 '24	Buy	1.82	6,648	12,075	360,723
DENYES NANCY	General Counsel	Jun 05 '24	Buy	1.86	5,000	9,276	22,267
COUGHLIN TIMOTHY	Director	May 30 '24	Buy	1.75	50,000	87,500	56,000
Broadfoot Jill Marie	Chief Financial Officer	May 31 '24	Buy	1.79	5,000	8,950	27,960
Shukla Sanjay	President and CEO	May 31 '24	Buy	1.81	20,000	36,140	136,548
Broadfoot Jill Marie	Chief Financial Officer	Feb 06 '24	Sale	1.69	1,590	2,687	20,821
Shukla Sanjay	President and CEO	Dec 12 '23	Buy	1.18	12,000	14,136	106,173
Shukla Sanjay	President and CEO	Dec 11 '23	Buy	1.17	3,000	3,510	94,173
Shukla Sanjay	President and CEO	Nov 13 '23	Buy	1.11	13,578	15,085	91,173

Atyr Pharma Inc (LIFE)

Atyr Pharma Inc Stock (LIFE) Company Profile

Atyr Pharma Inc Stock (LIFE) Upgrades & Downgrades

Atyr Pharma Inc (LIFE) 最新ニュース

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 27.1% in August - MarketBeat

Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily

ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha

Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily

Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News

Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex

Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World

Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada

Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat

Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN

Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World

Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News

Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World

Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World

Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK

aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire

aTyr Pharma to Participate in September Investor Conferences - StockTitan

ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com

Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com

Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex

aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com

aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com

aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com

ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat

Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World

Q3 2024 Earnings Forecast for Atyr PHARMA INC Issued By HC Wainwright (NASDAQ:ATYR) - MarketBeat

ATYR’s Stock Market Adventure: 41.84% YTD Growth Amidst Volatility - The InvestChronicle

ATYR (aTyr Pharma) Cash From Discontinued Investing Activit - GuruFocus.com

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance

HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - MarketBeat

Atyr PHARMA INC to Post FY2028 Earnings of $4.72 Per Share, HC Wainwright Forecasts (NASDAQ:ATYR) - Defense World

Atyr PHARMA (NASDAQ:ATYR) Receives “Outperform” Rating from Royal Bank of Canada - Defense World

Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results, Beats Expectations By $0.01 EPS - Defense World

Atyr PHARMA (NASDAQ:ATYR) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Atyr PHARMA (NASDAQ:ATYR) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Piper Sandler maintains Overweight rating on aTyr Pharma shares By Investing.com - Investing.com UK

Atyr Pharma: Q2 Earnings Snapshot - CT Insider

Atyr Pharma: Q2 Earnings Snapshot - Darien Times

Atyr Pharma: Q2 Earnings Snapshot - CTPost

ATYR (aTyr Pharma) Profitability Rank : 1 (As of Mar. 2024) - GuruFocus.com

ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024 - InvestorPlace

Atyr Pharma Inc (LIFE) 財務データ

収益

当期純利益

現金流量

EPS

Atyr Pharma Inc (LIFE) インサイダートレーディング

LIFEに似た銘柄